Financing: SMA-TB has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847762
Duration: January 2020 – June 2024
The SMA-TB consortium involves 7 institutions at the forefront of TB, brought together by the Coordinator to meet the scientific aim and objectives of the project while matching the scope and specific challenge of the call. The partners have a long track of previous collaborative activities and associations. Each partner has been included by his/her background experience both in science and in multinational collaboration in the field of TB. The consortium is complemented with two SME.
Tuberculosis (TB) is a chronic, life-threatening infectious disease which poses a tremendous challenge for physicians, researchers and Health Systems, which treatment is long, based only on the drug susceptibility of the responsible infective strain and very costly in drug-resistant cases (MDR-TB). The European Region still has the highest prevalence of MDR-TB in the world.
Host-Directed Therapies (HDT) have been recently proposed to shorten treatment length and by to improve the patients’ outcomes while not increasing the risk of generating drug resistance. As hyperinflammation is responsible of the lung damage associated to patients’ worse outcomes and sequelae, one of the approaches is to add an HDT with anti-inflammatory effect to the current drug regimen to cure the patients faster while having less permanent lung damage. Because TB has a wide range of clinical forms and severity stages, any therapeutic regimen needs to be studied in Clinical Trials (CT) as its benefit might differ among patients. No individualized personalized medicine is possible without stratifying the patients by integrating pathogen and host factors that will predict the course of the disease and the response to the intervention.
The overall objectives of SMA-TB project are: